MedPath
Found 4 clinical trials|View Analysis
Sort by:

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

Phase 3
Not yet recruiting
Conditions
Advanced High-Grade Epithelial Ovarian
Primary Peritoneal
Fallopian Tube Cancers
High Folate Receptor-Alpha Expression
Platinum Resistant
Interventions
First Posted Date
2024-11-11
Last Posted Date
2024-11-11
Lead Sponsor
AbbVie
Target Recruit Count
110
Registration Number
NCT06682988

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Phase 3
Active, not recruiting
Conditions
Ovarian Neoplasm
Fallopian Tube Neoplasms
Peritoneal Neoplasms
Interventions
Drug: Nab-paclitaxel 80 mg/m^2
Drug: Nab-paclitaxel 100 mg/m^2
Drug: Relacorilant 150 mg once daily (QD)
First Posted Date
2022-02-25
Last Posted Date
2024-08-05
Lead Sponsor
Corcept Therapeutics
Target Recruit Count
360
Registration Number
NCT05257408
Locations
🇺🇸

Site 272, Atlanta, Georgia, United States

🇺🇸

Site 339, Indianapolis, Indiana, United States

🇺🇸

Site 127, Pittsburgh, Pennsylvania, United States

and more 113 locations

A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

Phase 3
Completed
Conditions
Peritoneal Cancer
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Interventions
First Posted Date
2020-03-05
Last Posted Date
2024-08-07
Lead Sponsor
ImmunoGen, Inc.
Target Recruit Count
106
Registration Number
NCT04296890
Locations
🇺🇸

St. Vincent Gynecologic Oncology, Indianapolis, Indiana, United States

🇦🇺

St John of God Subiaco Hospital, Subiaco, Western Australia, Australia

🇮🇱

Shaare Zedek Medical Center, Jerusalem, Israel

and more 86 locations

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

Phase 3
Completed
Conditions
Epithelial Ovarian Cancer
Peritoneal Cancer
Fallopian Tube Cancer
Interventions
First Posted Date
2019-12-24
Last Posted Date
2025-01-07
Lead Sponsor
AbbVie
Target Recruit Count
453
Registration Number
NCT04209855
Locations
🇺🇸

Illinois Cancer Specialists, Arlington Heights, Illinois, United States

🇺🇸

Cleveland Clinic, Cleveland, Ohio, United States

🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, China

and more 210 locations
© Copyright 2025. All Rights Reserved by MedPath